Specialty drug spend spotlight: Oncology
Oncology treatments are driving the drug pipeline
Oncology therapies continue to drive a major part of the 2025 pipeline, evidenced by the 10 products that are on track for approval in the first half of the year. Many of the anticipated approvals are for novel therapies that may set new standards of care for their respective indication and have the potential to significantly impact the cancer treatment landscape throughout the year.
The early 2025 oncology pipeline highlights the continued innovation within this treatment category and includes therapies that target specific genetic mutations and areas where exiting treatment options are limited and span both pharmacy and medical benefit coverage.
Oncology quick facts
- U.S. oncology spending reached over 99 billion by the end of 2023 and is expected to continue growing.
- There are more that 30 oncology drugs pending approval by the FDA in 2025 with 2 drugs expected in Q1:
- Vimseltinib’s approval is expected 2/17/2025.
- Mirdametinib approval is expected 2/28/2025.
To see more drug trends and insights, visit the Insights Hub.
Read more
References
- IPD Analytics, December 2024
